Company Focus
Merck & Co
Latest Merck & Co News
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Latest News & Features of interest to Merck & Co
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
US clinical-stage biotech Kairos Pharma, which is focused on innovative cancer therapeutics, has provided a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from chief executive Dr John Yu. The firm’s shares rose 4.8% to $0.48 on the announcement. 5 June 2026
Generics
The US Supreme Court has handed a unanimous win to British drugmaker Hikma in a closely watched generics patent case brought by Irish biopharma Amarin. 5 June 2026
Biotechnology
US biotech Stipple Bio has signed a multi-target licensing agreement with Swiss life sciences supplier Lonza to support development of next-generation antibody-drug conjugates (ADCs), including its lead oncology candidate STP-100. 5 June 2026
Biotechnology
Parabilis Medicines announced today that it plans to raise up to $475 million through a US initial public offering. The biopharmaceutical company filed to offer 25 million shares priced between $17 and $19 each. 5 June 2026
Pharmaceutical
US antivirals specialist Gilead Sciences applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. 5 June 2026
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Biosimilars
Israel-headquartered Teva Pharmaceutical Industries has announced the launch of Ahzantive (aflibercept), a biosimilar to Eylea, in Europe further strengthening the company’s growing biosimilars portfolio and expanding its presence in ophthalmology. 4 June 2026
Biotechnology
CytomX Therapeutics announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals to create conditionally-activated bispecific cancer therapies utilizing CytomX’s Probody therapeutic platform and Regeneron’s Veloci-Bi bispecific antibody development platform. 4 June 2026
Biotechnology
Shares in Switzerland-based ADC Therapeutics fell sharply in pre-market trading on Thursday after investors focused on safety findings and the lack of a clear overall survival advantage in the Phase III LOTIS-5 trial of Zynlonta (loncastuximab tesirine-lpyl) plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 4 June 2026
Latest In Brief for Merck & Co
Pharmaceutical
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. 25 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze